En español

Menu

Publications

Quick Links

COVID-19 is an emerging, rapidly evolving situation.


Get the latest information from CDC (Coronavirus.gov) | NIH Resources | NIDA Resources

NIDA Notes Articles: Buprenorphine

NIDA Notes Category Graphic

AOUD Treatment in Primary Care Settings—Is it Feasible?

January 2020
Treatment for alcohol and opioid use disorders (AOUD) is feasible in primary care settings, but ongoing funding to support organizational capacity is critical for sustaining such programs.

NIDA Notes Category Graphic

Interim Buprenorphine Alleviates Psychiatric Symptoms in Waitlisted OUD Patients

March 2019
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.

NIDA Notes Category Graphic

New Studies Clarify Risk Factors for Neonatal Abstinence Syndrome

January 2019
A recent NIDA-sponsored study found higher rates of NAS among males than among females. A second study found that, among infants whose mothers were treated with buprenorphine while pregnant, NAS was more severe among those whose mothers used other substances.

NIDA Notes Category Graphic

As Opioid Use Disorders Increased, Prescriptions for Treatment Did Not Keep Pace

July 2018
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to staying in treatment.

NIDA Notes Category Graphic

Buprenorphine Benefits Waitlisted Seekers of Opioid Treatment

March 2017
In two pilot clinical trials, buprenorphine helped participants reduce their illicit opioid use and injection drug use while awaiting admission to a methadone or buprenorphine treatment program. Researchers minimized the risks for improper use or diversion of the study medication by giving it to trial participants in a computerized, tamper-proof device that dispenses one dose each day.

NIDA Notes Category Graphic

Dual Regimen Aims To Shorten Medication-Assisted Therapy

May 2016
Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.

NIDA Notes Category Graphic

ED-Initiated Buprenorphine Outperforms Referral or SBIRT for ED Patients With Opioid Addiction

January 2016
Emergency department visits present prime opportunities to identify people with opioid addiction and provide them with onsite initiation of treatment with buprenorphine/naloxone.

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics